Format

Send to

Choose Destination
Can J Ophthalmol. 2010 Jun;45(3):239-42. doi: 10.3129/i10-013.

Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study.

Author information

1
Department of Ophthalmology, Queen's University, Kingston, Ont.

Abstract

OBJECTIVE:

To determine the incidence and characteristics of acute intraocular inflammation after intravitreal bevacizumab injections from a tertiary care retinal practice.

DESIGN:

Retrospective cohort study.

PARTICIPANTS:

A consecutive series of patients who had received bevacizumab injections performed by a single surgeon.

METHODS:

We reviewed the records of all patients with severe anterior chamber inflammation and (or) vitritis after bevacizumab injections.

RESULTS:

A total of 693 bevacizumab injections were performed on 193 eyes of 173 patients between June 2006 and March 2008. There were a total of 9 cases of acute intraocular inflammation for an incidence of 1.30% (95% CI: 0.69%-2.47%). All patients had a worse visual acuity at the end of follow-up than on injection day. The mean loss of vision was 6.1 lines of Snellen visual acuity; one patient developed inflammation-induced glaucoma which required surgical intervention.

CONCLUSIONS:

Intravitreal injection of bevacizumab is associated with a low but significant risk of acute intraocular inflammation and may result in significant visual loss.

PMID:
20436545
DOI:
10.3129/i10-013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center